Plain-English translation of NCT07224776 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a small pilot study testing whether a medication called can help cancer patients who are experiencing kidney problems as a side effect of their cancer treatment. When certain cancer medications are used, some patients develop high levels of protein in their urine, which can be a sign of kidney stress. This study will see if the medication can reduce that protein loss and protect kidney health.
Cancer patients taking certain types of cancer drugs sometimes develop a side effect where their kidneys leak too much protein into the urine. Right now, there are limited treatment options for this specific problem, so researchers want to see if this medication might help protect patients' kidneys and prevent further damage.
You likely qualify if…
You likely don't qualify if…
If you join, you will take the medication starting at 200 mg daily for 2 weeks, then increase to 400 mg daily. You'll continue this dose through week 8, with regular visits to the research center for monitoring. After week 8, you'll return to your standard cancer care. The research team will track changes in your urine protein levels and watch for any side effects throughout the study.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States